Aravive Inc (NASDAQ:ARAV) Short Interest Update

Aravive Inc (NASDAQ:ARAV) saw a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 82,500 shares, a drop of 35.8% from the December 31st total of 128,500 shares. Currently, 1.2% of the shares of the company are sold short. Based on an average trading volume of 494,100 shares, the short-interest ratio is currently 0.2 days.

In other news, Director Srinivas Akkaraju bought 133,333 shares of Aravive stock in a transaction that occurred on Monday, December 2nd. The stock was bought at an average price of $11.30 per share, for a total transaction of $1,506,662.90. Company insiders own 39.80% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. grew its position in Aravive by 5.8% during the 2nd quarter. BlackRock Inc. now owns 173,943 shares of the company’s stock worth $1,044,000 after purchasing an additional 9,544 shares during the period. Vanguard Group Inc. grew its position in Aravive by 4.7% during the 2nd quarter. Vanguard Group Inc. now owns 159,034 shares of the company’s stock worth $955,000 after purchasing an additional 7,200 shares during the period. Alpine Global Management LLC acquired a new stake in Aravive during the 4th quarter worth about $1,391,000. Finally, Renaissance Technologies LLC grew its position in Aravive by 13.8% during the 2nd quarter. Renaissance Technologies LLC now owns 148,265 shares of the company’s stock worth $890,000 after purchasing an additional 18,017 shares during the period. 23.82% of the stock is currently owned by institutional investors.

ARAV traded down $0.18 during midday trading on Friday, hitting $10.73. 103,465 shares of the company were exchanged, compared to its average volume of 229,878. The company’s 50 day simple moving average is $12.65 and its 200 day simple moving average is $8.25. The firm has a market capitalization of $159.83 million, a price-to-earnings ratio of -1.77 and a beta of 2.52. The company has a current ratio of 7.59, a quick ratio of 7.59 and a debt-to-equity ratio of 0.18. Aravive has a 1-year low of $3.40 and a 1-year high of $15.62.

Aravive (NASDAQ:ARAV) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.04). On average, equities analysts anticipate that Aravive will post -1.75 EPS for the current year.

ARAV has been the subject of a number of research analyst reports. Wedbush raised their target price on Aravive from $12.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 20th. Zacks Investment Research upgraded Aravive from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Wednesday. HC Wainwright reduced their target price on Aravive from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, December 20th. Cantor Fitzgerald initiated coverage on Aravive in a research note on Monday, December 9th. They issued an “overweight” rating and a $30.00 target price for the company. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $31.00 target price on shares of Aravive in a research note on Friday, December 20th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Aravive has an average rating of “Buy” and a consensus price target of $25.40.

About Aravive

Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.

Recommended Story: P/E Growth (PEG)

Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit